Peptides for inducing cytotoxic T lymphocyte responses to hepatitus B virus
AssigneeThe Scripps Research Institute
InventorsFrancis V. Chisari, Carlo Ferrari, Amalia Penna, Gabriele Missael
Life of this patent
Estimating the term…
Abstract
Peptides are used to define epitopes that stimulate HLA-restricted cytotoxic T lymphocyte activity against hepatitis B virus antigens. The peptides are derived from regions of HBV polymerase, and are particularly useful in treating or preventing HBV infection, including methods for stimulating the immune response of chronically infected individuals to respond to HBV antigens.
Claims65
An HBV immunogenic peptide composition comprising an immunogenic peptide of 50 amino acids or less in length, wherein said peptide comprises at least one of the following:
- at least four contiguous amino acids of an amino acid sequence of HBc19-27, or at least 10 contiguous amino acids of an amino acid sequence of HBc140-154;
- and further wherein the peptide, or a fragment thereof, binds to an appropriate HLA molecule to form a complex recognized by cytotoxic T cells which T cells recognize a native HBV core protein antigen.
A method of stimulating a cytotoxic T cell response, said method comprising:
- providing an HBV immunogenic peptide of 50 amino acids or less in length wherein said peptide comprises at least one of the following:
- at least four contiguous amino acids of an amino acid sequence of HBc19-27, or at least 10 contiguous amino acids of an amino acid sequence of HBc140-154;
- complexing the peptide, or a fragment thereof, with an appropriate HLA molecule;
- and,
- contacting an HLA-restricted CTL, which T cell recognizes a native HBV core protein antigen, with the complex of the provided peptide and the HLA molecule, whereby a CTL response is stimulated.
An HBV immunogenic peptide composition comprising a peptide of 20 amino acids or less in length, wherein the peptide comprises at least seven contiguous amino acids of HBc28-47;
- and further, wherein the peptide, or a fragment thereof, binds to an appropriate HLA molecule to form a complex recognized by cytotoxic T cells which T cells recognize a native HBV core protein antigen.
A method of stimulating a cytotoxic T cell response, said method comprising:
- providing an HBV immunogenic peptide of 20 amino acids or less in length, wherein the peptide comprises at least seven contiguous amino acids of HBc28-47;
- complexing the peptide, or a fragment thereof, with an appropriate HLA molecule;
- and,
- contacting an HLA-restricted CTL, which T cell recognizes a native HBV core protein antigen, with the complex of the provided peptide and the HLA molecule, whereby a CTL response is stimulated.
An HBV immunogenic peptide composition comprising a peptide of 17 amino acids or less in length, wherein the peptide comprises at least seven contiguous amino acids of HBc111-125;
- and further, wherein the peptide, or a fragment thereof, binds to an appropriate HLA molecule to form a complex recognized by cytotoxic T cells which T cells recognize a native HBV core protein antigen.
A method of stimulating a cytotoxic T cell response, said method comprising:
- providing an immunogenic peptide of 17 amino acids or less in length, wherein the peptide comprises at least seven contiguous amino acids of HBc111-125;
- complexing the peptide, or a fragment thereof, with an appropriate HLA molecule;
- and,
- contacting an HLA-restricted CTL, which T cell recognizes a native HBV core protein antigen, with the complex of the provided peptide and the HLA molecule, whereby a CTL response is stimulated.
Dependencies are inferred from the claim text.